Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1658 - Docetaxel, Cisplatin, and 5-fluorouracil (DCF) chemotherapy in the treatment of metastatic or unresectable locally recurrent anal squamous cell carcinoma: a phase II study of French interdisciplinary GERCOR and FFCD Groups (Epitopes-HPV02 study)

Date

09 Sep 2017

Session

Poster display session

Presenters

Stefano Kim

Citation

Annals of Oncology (2017) 28 (suppl_5): v158-v208. 10.1093/annonc/mdx393

Authors

S. Kim1, E. Francois2, F. Bidard3, E. Samalin4, F. El Hajbi5, N. Baba-Hamed6, S. Dumont7, S. Pernot8, D. Peiffert9, F. Ghiringhelli10, O. Bouche11, J. Desrame12, M. Zoubir13, A. Parzy14, D. Smith15, C. de la Fouchardiere16, B. Buecher3, V. Vendrely17, F. Bonnetain18, C. Borg1

Author affiliations

  • 1 Medical Oncology, CHU Besançon, Hôpital Jean Minjoz, 25030 - Besançon/FR
  • 2 Medical Oncology, Centre Antoine Lacassagne, Nice/FR
  • 3 Oncology, Institut Curie, 75248 cedex5 - Paris/FR
  • 4 Medical Oncology, ICM Regional Cancer Institute of Montpellier, 34298 - Montpellier/FR
  • 5 Oncology, Centre Oscar Lambret, Lille/FR
  • 6 Oncology, Groupe Hospitalier Paris Saint-Joseph, Paris/FR
  • 7 Oncology, Hopital St. Antoine, 75571 - Paris/FR
  • 8 Oncology, Hôpital européen Georges-Pompidou, Paris/FR
  • 9 Oncology, Institut de Cancérologie de Lorraine, Nancy/FR
  • 10 Medical Oncology, Georges-Francois Leclerc Cancer Center, 21000 - Dijon/FR
  • 11 Department Of Medicine-oncology, CHU Robert Debré, Reims/FR
  • 12 Hepato-gastroenterology, Hôpital privé Jean Mermoz, 69373 - Lyon/FR
  • 13 Oncology, Hôpital Privé des Peupliers, Paris/FR
  • 14 Oncology, Centre Francois Baclesse, 14076 - Caen/FR
  • 15 Oncology, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 16 Oncology, Centre Léon Bérard, 69008 - Lyon/FR
  • 17 Radiotherapy, CHU Bordeaux Hopital St. André, 33000 - Bordeaux/FR
  • 18 Methodological And Quality Of Life Unit In Oncology (inserm Umr 1098), University Hospital Jean Minjoz, 25000 - Besançon/FR
More

Resources

Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 1658

Background

Anal Squamous Cell Carcinoma (ASCC) is a rare disease, but its incidence is markedly increasing. To date, in advanced ASCC, no standard regimen exists. We have previously published the potential role of DCF regimen. Among 8 advanced ASCC consecutive patients who relapsed after CRT, the DCF regimen induced a complete response in 4 patients, including 3 pathological complete responses. Thus, this study was designed to confirm the interest of DCF regimen in advanced ASCC patients.

Methods

A multicentre phase II trial was conducted among 25 hospitals in France. Main eligibility criteria were histologically proved unresectable locally advanced recurrent or metastatic ASCC, ECOG-PS vs. 

Results

66 patients were enrolled from September 2014 to January 2017. Median age was 60.05 years (range, 38-78) with female predominance (81.8%). 40 (60.6%) patients had locoregional involvement at enrolment, and the most frequent metastatic sites were liver (60.6%), distal lymph node (48.5%), and lung (36.4%). At interim analysis, 10 (47.6%) patients were progression-free at 12 months from the first DCF cycle. To date, 65 patients are assessable for response rate by investigators. The objective response rate is 87.7%, including 36.9% of complete responses. Among the first 32 patients with ≥12 months of follow-up, 15 (46.9%) patients were progression-free at 12 months.

Conclusions

This first ever conducted prospective trial in front-line advanced ASCC demonstrated a high long-lasting response rate of the DCF regimen. DCF regimen should then be considered as a standard of care in this situation.

Clinical trial identification

NCT02402842

Legal entity responsible for the study

University Hospital of Besancon

Funding

Research grant from the University Hospital of Besançon

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings